© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
June 21, 2021
The study follows a successful phase 1b/2 study, data from which were presented at the 2021 ASCO Annual Meeting.
June 18, 2021
"As someone once told me, if you make a change in your golf swing and it is easy, more than likely you have not changed anything," writes Raoul S. Concepcion, MD, FACS.
June 17, 2021
Two experts in the management of prostate cancer provide key insight into the value of blood and urine liquid biopsy tests when deciding whether to perform a prostate tissue biopsy.
Thought leaders in the management of prostate cancer build a discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort.
June 15, 2021
The Decipher Prostate genomic classifier identified biomarkers associated with improved apalutamide outcomes in nonmetastatic castration-resistant prostate cancer.
Embracing and understanding new and emerging molecular techniques will improve patient outcomes.
June 10, 2021
Experts urologists, David Albala, MD and Judd W. Moul, MD, compare the utility of a variety of blood and urine tests for screening and diagnosing prostate cancer.
Key opinion leaders in urology provide an overview of the prevalence of prostate cancer and discuss the importance of screening and risk assessment tools like the Prostate-Specific Antigen (PSA) test.
June 03, 2021
Agarwal also discusses the ongoing phase 3 randomized CONTACT-02 study.
June 01, 2021
PARP inhibitors are recent additions to the prostate cancer armamentarium and adverse event management is critical to their optimal integration into clinical practice.